NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

Perhaps doing some research would show you that is not true. Optune had 5 year overall survival of 13% vs. 5% for the comparator. From the ASCO Post:

A landmark analysis showed improved survival for the combination of tumor-treating fields plus temozolomide vs temozolomide alone at 2 (43% vs 31%, respectively), 3 (26% vs 16%), 4 (20% vs 8%), and 5 years (13% vs 5%) from randomization.

https://ascopost.com/issues/may-10-2017/out-of-the-box-approach-plus-temozolomide-extends-survival-in-glioblastoma

This was accomplished without manipulating the protocol, endpoints, comparator or SAP and without any OS data confounding.